ERK1/2 Inhibition via the Oral Administration of Tizaterkib Alleviates Noise-Induced Hearing Loss While Tempering down the Immune Response
International Journal of Molecular Sciences · 07.06.2024 · 25 (12) · 6305
DOI: 10.3390/ijms25126305 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 07.06.2024. Verfasst von Richard D Lutze und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Neuroscience, School of Medicine, Creighton University, Omaha, NE 68178, USA. Hauptthemen laut MEDLINE: Hearing Loss, Noise-Induced. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, American Hearing Research Foundation, NCRR NIH HHS.
Abstract (Originalsprache)
Noise-induced hearing loss (NIHL) is a major cause of hearing impairment and is linked to dementia and mental health conditions, yet no FDA-approved drugs exist to prevent it. Downregulating the mitogen-activated protein kinase (MAPK) cellular pathway has emerged as a promising approach to attenuate NIHL, but the molecular targets and the mechanism of protection are not fully understood. Here, we tested specifically the role of the kinases ERK1/2 in noise otoprotection using a newly developed, highly specific ERK1/2 inhibitor, tizaterkib, in preclinical animal models. Tizaterkib is currently being tested in phase 1 clinical trials for cancer treatment and has high oral bioavailability and low predicted systemic toxicity in mice and humans. In this study, we performed dose–response measurements of tizaterkib’s efficacy against permanent NIHL in adult FVB/NJ mice, and its minimum effective dose (0.5 mg/kg/bw), therapeutic index (>50), and window of opportunity (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Neuroscience, School of Medicine, Creighton University, Omaha, NE 68178, USA.
- The Scintillon Research Institute, San Diego, CA 92121, USA.
ORCID-Profile: Tal Teitz
Förderung
- NIGMS NIH HHS
- American Hearing Research Foundation
- NCRR NIH HHS
- NIDCD NIH HHS
- NIH HHS
- National Institutes of Health NIDCD
- American Hearing Research Foundation 2020
Zitieren
APA
Lutze, R. D., Ingersoll, M. A., Thotam, A., Joseph, A., Fernandes, J., & Teitz, T. (2024). ERK1/2 Inhibition via the Oral Administration of Tizaterkib Alleviates Noise-Induced Hearing Loss While Tempering down the Immune Response. International Journal of Molecular Sciences, 25(12), 6305. https://doi.org/10.3390/ijms25126305
Vancouver
Lutze RD, Ingersoll MA, Thotam A, Joseph A, Fernandes J, Teitz T. ERK1/2 Inhibition via the Oral Administration of Tizaterkib Alleviates Noise-Induced Hearing Loss While Tempering down the Immune Response. International Journal of Molecular Sciences. 2024;25(12):6305. doi:10.3390/ijms25126305
BibTeX
@article{Lutze2024,
author = {Lutze, Richard D and Ingersoll, Matthew A and Thotam, Alena and Joseph, Anjali and Fernandes, Joshua and Teitz, Tal},
title = {ERK1/2 Inhibition via the Oral Administration of Tizaterkib Alleviates Noise-Induced Hearing Loss While Tempering down the Immune Response},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {12},
pages = {6305},
doi = {10.3390/ijms25126305}
}
EUVIMED